It is thought that various immunomodulatory drugs can induce primary cutaneous anaplastic large cell lymphoma in patients, including the fingolimod used to treat relapsing-remitting multiple sclerosis, as well as the tumor necrosis factor (TNF) blocker adalimumab used to treat various autoimmune diseases [134,135]. Here, TNF is linked to relapsing-remitting multiple sclerosis.